Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BWAY Brainsway	$13.15 +2.7%	$10.50	$5.67 ▼ $13.35	$241.85M	1.4	67,672 shs	33,240 shs
EDTXF Spectral Diagnostics	$0.60 -0.7%	$0.61	$0.32 ▼ $0.65	$172.23M	0.22	6,291 shs	19,000 shs
LQDA Liquidia Technologies	$12.25 +1.5%	$15.10	$8.26 ▼ $19.41	$1.03B	-0.01	1.26 million shs	1.03 million shs
PAVM PAVmed	$0.60 +1.0%	$0.66	$0.55 ▼ $1.90	$10.10M	1.06	135,585 shs	19,874 shs
XAIR Beyond Air	$0.18 +0.7%	$0.19	$0.15 ▼ $0.68	$15.36M	0.22	1.54 million shs	702,165 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BWAY Brainsway	+2.73%	+0.38%	+29.05%	+48.59%	+121.75%
EDTXF Spectral Diagnostics	-0.73%	+0.32%	+0.08%	+19.40%	+68.68%
LQDA Liquidia Technologies	+1.53%	-4.56%	-25.92%	-5.08%	+2.38%
PAVM PAVmed	+1.02%	-3.38%	-0.42%	+0.34%	-15.68%
XAIR Beyond Air	+0.67%	+9.61%	-4.69%	-25.91%	-69.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BWAY Brainsway	1.4092 of 5 stars	1.5	3.0	0.0	0.0	1.9	0.8	1.9
EDTXF Spectral Diagnostics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	3.3875 of 5 stars	4.5	0.0	0.0	0.0	2.0	4.2	0.6
PAVM PAVmed	4.3645 of 5 stars	3.5	5.0	0.0	4.3	0.0	0.0	1.9
XAIR Beyond Air	4.155 of 5 stars	3.7	3.0	0.0	3.5	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BWAY Brainsway	3.00	Buy	$14.25	8.37% Upside
EDTXF Spectral Diagnostics	0.00	N/A	N/A	N/A
LQDA Liquidia Technologies	3.00	Buy	$26.89	119.59% Upside
PAVM PAVmed	3.00	Buy	$19.00	3,082.58% Upside
XAIR Beyond Air	3.33	Buy	$1.50	737.99% Upside

Current Analyst Ratings Breakdown

Latest PAVM, EDTXF, BWAY, XAIR, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$23.00 ➝ $25.00
6/11/2025	LQDA Liquidia Technologies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $23.00
6/9/2025	BWAY Brainsway	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/6/2025	PAVM PAVmed	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.50 ➝ $19.00
6/2/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	LQDA Liquidia Technologies	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$36.00 ➝ $37.00
5/28/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $23.00
5/28/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/28/2025	LQDA Liquidia Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $35.00
5/27/2025	LQDA Liquidia Technologies	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/21/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BWAY Brainsway	$41.02M	6.06	$0.26 per share	51.33	$3.31 per share	3.97
EDTXF Spectral Diagnostics	$1.67M	102.38	N/A	N/A	($0.07) per share	-8.55
LQDA Liquidia Technologies	$14M	74.77	N/A	N/A	$0.91 per share	13.46
PAVM PAVmed	$2.99M	3.41	N/A	N/A	($0.92) per share	-0.65
XAIR Beyond Air	$3.70M	4.18	N/A	N/A	$0.17 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BWAY Brainsway	$2.92M	$0.20	65.75	82.19	N/A	9.01%	7.35%	4.72%	8/5/2025 (Estimated)
EDTXF Spectral Diagnostics	-$11.24M	-$0.07	N/A	∞	N/A	-1,078.10%	N/A	-336.97%	8/7/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.58	N/A	N/A	N/A	-903.80%	-177.91%	-60.15%	8/6/2025 (Estimated)
PAVM PAVmed	$39.79M	$0.71	0.84	N/A	N/A	3,711.54%	N/A	-42.29%	8/12/2025 (Estimated)
XAIR Beyond Air	-$46.62M	-$0.79	N/A	N/A	N/A	-1,258.46%	-233.96%	-113.92%	8/5/2025 (Estimated)

Latest PAVM, EDTXF, BWAY, XAIR, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/17/2025	Q4 2025	XAIR Beyond Air	-$0.14	-$0.09	+$0.05	-$0.09	$1.39 million	$1.15 million
5/13/2025	Q1 2025	BWAY Brainsway	$0.02	$0.04	+$0.02	$0.04	$11.45 million	$11.54 million
5/9/2025	Q1 2025	EDTXF Spectral Diagnostics	N/A	-$0.03	N/A	-$0.03	N/A	$0.40 million
5/8/2025	Q1 2025	LQDA Liquidia Technologies	-$0.42	-$0.45	-$0.03	-$0.45	$3.23 million	$3.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BWAY Brainsway	N/A	N/A	N/A	N/A	N/A
EDTXF Spectral Diagnostics	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A
PAVM PAVmed	N/A	N/A	N/A	N/A	N/A
XAIR Beyond Air	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BWAY Brainsway	N/A	5.03	4.75
EDTXF Spectral Diagnostics	N/A	0.09	0.08
LQDA Liquidia Technologies	2.08	2.93	2.91
PAVM PAVmed	N/A	0.37	0.37
XAIR Beyond Air	0.64	3.20	2.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BWAY Brainsway	30.11%
EDTXF Spectral Diagnostics	N/A
LQDA Liquidia Technologies	64.54%
PAVM PAVmed	19.93%
XAIR Beyond Air	31.50%

Insider Ownership

Company	Insider Ownership
BWAY Brainsway	19.00%
EDTXF Spectral Diagnostics	1.50%
LQDA Liquidia Technologies	26.50%
PAVM PAVmed	7.30%
XAIR Beyond Air	19.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BWAY Brainsway	120	18.90 million	15.31 million	Not Optionable
EDTXF Spectral Diagnostics	29	285.52 million	281.24 million	Not Optionable
LQDA Liquidia Technologies	50	85.49 million	62.83 million	Optionable
PAVM PAVmed	90	17.09 million	15.85 million	Optionable
XAIR Beyond Air	70	86.37 million	69.61 million	Optionable

PAVM, EDTXF, BWAY, XAIR, and LQDA Headlines

Recent News About These Companies

Beyond Air Inc.

June 26, 2025 | barrons.com

Here's Why Beyond Air (XAIR) Could be Great Choice for a Bottom Fisher

June 26, 2025 | zacks.com

Beyond Air (XAIR) Q4 2025 Earnings Call Transcript

June 21, 2025 | msn.com

Beyond Air, Inc. (NASDAQ:XAIR) Q4 2025 Earnings Call Transcript

June 20, 2025 | msn.com

Beyond Air posts narrower-than-feared Q4 loss, shares surge 15%

June 18, 2025 | investing.com

Beyond Air Reports Strong Revenue Growth and Strategic Advances

June 17, 2025 | tipranks.com

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

June 17, 2025 | seekingalpha.com

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | finance.yahoo.com

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

June 17, 2025 | zacks.com

Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know

June 17, 2025 | benzinga.com

Beyond AirÂ® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | globenewswire.com

Beyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide Generator

June 16, 2025 | quiverquant.comQ

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

June 16, 2025 | globenewswire.com

Beyond Oil Issues Clarification Regarding Previous German-Language Media Activities

June 3, 2025 | globenewswire.com

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

May 20, 2025 | globenewswire.com

Beyond Air granted U.S. patent for gaseous nitric oxide delivery

April 25, 2025 | markets.businessinsider.com

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

April 25, 2025 | finance.yahoo.com

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

April 25, 2025 | finance.yahoo.com

Beyond Air Gets Patent for Lung Infection Treatment

April 25, 2025 | marketwatch.com

Beyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric Oxide

April 25, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PAVM, EDTXF, BWAY, XAIR, and LQDA Company Descriptions

Brainsway NASDAQ:BWAY

$13.15 +0.35 (+2.73%)

As of 07/3/2025 02:51 PM Eastern

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Spectral Diagnostics OTCMKTS:EDTXF

$0.60 0.00 (-0.73%)

As of 07/3/2025 12:06 PM Eastern

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Liquidia Technologies NASDAQ:LQDA

$12.24 +0.19 (+1.53%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$12.24 0.00 (0.00%)

As of 07/3/2025 04:23 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

PAVmed NASDAQ:PAVM

$0.60 +0.01 (+1.02%)

Closing price 07/3/2025 03:54 PM Eastern

Extended Trading

$0.60 0.00 (0.00%)

As of 07/3/2025 04:13 PM Eastern

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Beyond Air NASDAQ:XAIR

$0.18 +0.00 (+0.67%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$0.18 0.00 (-0.56%)

As of 07/3/2025 04:57 PM Eastern

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time